Coronavirus Update: Our team is here to help our clients and readers navigate these difficult times. Visit our Resources page now »

Skip to Main Content

About Fougera Pharmaceuticals Inc.

Fougera Pharmaceuticals (formerly Nycomed US) is focused on making specialty topical and dermatology medicines for North Americans. The company's E. Fougera & Company division primarily makes generic topical steroids, antibiotics, and antifungals for both prescription and OTC markets, while the PharmaDerm unit develops, manufactures, and markets branded prescription dermatology products. Its smaller Savage Laboratories unit makes prescription topicals for the emergency care market. Fougera separated from former parent Nycomed International in 2011 when it was bought by an investment group led by Nordic Capital. Investors sold Fougera to Sandoz in 2012.


Fougera operates two manufacturing facilities in New York State.

Sales and Marketing

The company's PharmaDerm prescription products are marketed to health care professionals (especially dermatologists) through its direct sales force (located in New York), while Fougera & Co.'s generic offerings are supplied by sales representatives (located in New Jersey) and through wholesale distributors and retail outlets. Savage Labs sells surgical lubricant Surgilube and emergency cardiology ointment Nitro-Bid to hospital pharmacies; it stopped marketing two other products, Crofab (antivenin for snake bites) and Digifab (an antidote for digitalis poisoning).


The company has grown its operations over the years through both internal research and development efforts and through selective acquisitions.

Company Background

Formerly owned by ALTANA AG, the company (then named Altana Inc.) was bought by Nycomed in 2007, along with ALTANA AG's other pharmaceutical operations, and was renamed Nycomed US. In September 2011 Nycomed International was acquired by Japanese drugmaker Takeda Pharmaceutical for €9.6 billion ($14 billion); however, the autonomous Nycomed US business didn't fit into Takeda's global growth strategy and was excluded from the deal. Following Nycomed International's acquisition by Takeda, Nycomed US changed its name to Fougera Pharmaceuticals. The firm was owned by the same private investor group (including Nordic Capital, Credit Suisse, Collier International, and Avista Capital Partners) that previously owned Nycomed International; the investor group sold Fougera to Sandoz less than a year later.

Fougera Pharmaceuticals Inc.

60 Baylis Rd
Melville, NY 11747-3838
Phone: 1 (631) 454-7677

Firm Stats

Employer Type: Privately Owned
Director FpandA: Frank Dona
Director Of Validation: Charles Tiranno
Employees (This Location): 250
Employees (All Locations): 880

Major Office Locations

Melville, NY

Other Locations

Wallingford, CT
East Hanover, NJ
Hicksville, NY
Melville, NY